CAJ | 학술논문

目的检测CD90及端粒酶逆转录酶(hTERT)在原发性肝癌中的表达,研究其蛋白产物在原发性肝癌发生、发展过程中的表达特点及相互关系.方法应用免疫组化S-P法检测36例原发性肝癌中CD90、hTERT的表达,并以同期20例正常肝组织作对照.结果肝癌组织中CD90、hTERT基因蛋白产物阳性表达率(分别为63.9％和47.2％)显著高于良性对照组(CD90、hTERT均阴性)；CD90、hTERT蛋白在UICC临床分期Ⅲ～Ⅳ期肝癌患者(分别为79.1％和62.5％)明显高于Ⅰ～Ⅱ期患者(分别为33.3％和16.6％)；CD90、hTERT两者呈正相关；CD90、hTERT阳性患者生存率(术后中位生存时间分别为85 d和76 d)明显低于CD90、hTERT阴性患者(术后中位生存时间分别为505 d和463 d),log秩检验显示生存率差异均有统计学意义.结论 CD90可能与肝癌的发生、发展相关,有望成为判断患者预后的指标之一.
목적 검측CD90급단립매역전록매(hTERT)재원발성간암중적표체,연구기단백산물재원발성간암발생、발전과정중적표체특점급상호관계.방법 응용면역조화S-P법검측36례원발성간암중CD90、hTERT적표체,병이동기20례정상간조직작대조.결과 간암조직중CD90、hTERT기인단백산물양성표체솔(분별위63.9％화47.2％)현저고우량성대조조(CD90、hTERT균음성)；CD90、hTERT단백재UICC림상분기Ⅲ～Ⅳ기간암환자(분별위79.1％화62.5％)명현고우Ⅰ～Ⅱ기환자(분별위33.3％화16.6％)；CD90、hTERT량자정정상관；CD90、hTERT양성환자생존솔(술후중위생존시간분별위85 d화76 d)명현저우CD90、hTERT음성환자(술후중위생존시간분별위505 d화463 d),log질검험현시생존솔차이균유통계학의의.결론 CD90가능여간암적발생、발전상관,유망성위판단환자예후적지표지일.
Objective To study the expressions of CD90 and hTERT in hepatocellular carcinoma (HCC),and their relationships to progression of tumor.Methods The expressions of CD90 and hTERT in hepatocellular carcinoma were detected by S-P immunohistochemical staining.Twenty patients with hemangiomas of liver were used as control.Results Compared with the control group,the positive rates of CD90 and hTERT in HCC were significantly higher (63.9％ and 47.2％ vs 0％ and 0％).The positive rates of CD90 and hTERT were significantly higher in patients with tumors at UICC Ⅲ-Ⅳ stage than at UICC stage Ⅰ -Ⅱ (79.1％ and 62.5％ vs 33.3％ and 16.6％).The CD90 expression correlated with hTERT positively.There were significant differences in survival between patients with CD90+ and CD90- or hTERT+ and hTERT-.The median postoperative survivals for patients with CD90+ and hTERT+,CD90- and hTERT- were 85 d and 76 d,505 d and 463 d,respectively.Conclusions CD90 expression correlated positively with progression of HCC.It has the potential to serve as a prognostic marker for HCC.